Polyunsaturated fatty acids in plasma at 8 years and subsequent allergic disease - 04/08/18
Abstract |
Background |
Polyunsaturated fatty acids (PUFAs) are hypothesized to modulate the risk of allergic disease. However, evidence from previous studies is inconclusive, and limited longitudinal data exist using circulating biomarkers of PUFA intake and metabolism.
Objective |
We aimed to investigate associations between n-3 and n-6 PUFAs at age 8 years and asthma, rhinitis, and aeroallergen sensitization at age 16 years.
Methods |
Proportions of n-3 PUFAs (very long-chain n-3 [VLC n-3; sum of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid] and α-linolenic acid) and n-6 PUFAs (linoleic acid and arachidonic acid [AA]) in blood samples at age 8 years were measured for 940 children from the prospective Swedish birth cohort BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiology). Allergic disease phenotypes were defined by using questionnaires and IgE measures at the ages of 8 and 16 years. Logistic regression was used to examine potential associations.
Results |
A higher proportion of total VLC n-3 PUFAs in plasma at age 8 years was associated with a reduced risk of prevalent asthma, rhinitis, and aeroallergen sensitization at age 16 years and with incidence of asthma between 8 and 16 years (adjusted odds ratio, 0.67; 95% CI, 0.47-0.94). AA was associated with a reduced risk of asthma, aeroallergen sensitization, and allergic rhinitis. The findings were most evident for allergic phenotypes of asthma and rhinitis. Additionally, AA was associated with an increased probability of asthma and rhinitis remission between 8 and 16 years of age.
Conclusion |
Higher proportions of certain VLC n-3 and very long-chain n-6 PUFAs in plasma phospholipids at age 8 years were associated with a reduced risk of allergic disease at age 16 years.
Le texte complet de cet article est disponible en PDF.Key words : Adolescent, allergy, asthma, Children, Allergy, Milieu, Stockholm, Epidemiology study, children, fatty acid, rhinitis, plasma, prospective studies
Abbreviations used : AA, ALA, DHA, DPA, EPA, FFQ, LA, OR, PUFA, VLC n-3
Plan
| Supported by the Stockholm County Council; the Swedish Research Council; the Swedish Research Council Formas; the Swedish Heart-Lung Foundation; the Swedish Asthma and Allergy Association; the Swedish Research Council for Health, Working Life and Welfare; and the European Commission's Seventh Framework 29 Program MeDALL (grant agreement no. 261357). Thermo Fisher Scientific kindly provided the reagents. |
|
| Disclosure of potential conflict of interest: A. Bergström's institution received grants from the Swedish Research Council; the Swedish Research Council for Health, Working Life and Welfare; and the Swedish Asthma and Allergy Association for this work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 2
P. 510 - août 2018 Retour au numéro
Article précédent
- Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
- Verena Niederberger, Angela Neubauer, Philippe Gevaert, Mihaela Zidarn, Margitta Worm, Werner Aberer, Hans Jørgen Malling, Oliver Pfaar, Ludger Klimek, Wolfgang Pfützner, Johannes Ring, Ulf Darsow, Natalija Novak, Roy Gerth van Wijk, Julia Eckl-Dorna, Margarete Focke-Tejkl, Milena Weber, Hans-Helge Müller, Joachim Klinger, Frank Stolz, Nora Breit, Rainer Henning, Rudolf Valenta
- TNF-?–induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-? blockade–driven IL-17A expression
- Paulo C.M. Urbano, Raúl Aguirre-Gamboa, Angel Ashikov, Bennie van Heeswijk, Anja Krippner-Heidenreich, Henk Tijssen, Yang Li, Valderilio F. Azevedo, Lisa J.T. Smits, Frank Hoentjen, Irma Joosten, Hans J.P.M. Koenen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?